Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR001 (Tildacerfont) in Adults with Classic Congenital Adrenal Hyperplasia
NCT03687242Phase 2Completed
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tildacerfont in congenital adrenal hyperplasia (CAH), sponsored by Spruce Biosciences, Inc. Primary endpoint: Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) at 12 weeks. Started Sep 2018; status: completed.
02
Drugs
tildacerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03687242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687242.